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Malignant melanoma possesses one of the highest metastatic potentials among human cancers. Acquisition of invasive phenotypes is a prerequisite for melanoma metastases. Elucidation of the molecular mechanisms underlying melanoma invasion will greatly enhance the design of novel agents for melanoma therapeutic intervention. Here, we report that guanosine monophosphate synthase (GMPS), an enzyme required for the de novo biosynthesis of GMP, has a major role in invasion and tumorigenicity of cells derived from either BRAF V600E or NRAS Q61R human metastatic melanomas. Moreover, GMPS levels are increased in metastatic human melanoma specimens compared with primary melanomas arguing that GMPS is an attractive candidate for anti-melanoma therapy. Accordingly, for the first time we demonstrate that angustmycin A, a nucleoside-analog inhibitor of GMPS produced by Streptomyces hygroscopius efficiently suppresses melanoma cell invasion in vitro and tumorigenicity in immunocompromised mice. Our data identify GMPS as a powerful driver of melanoma cell invasion and warrant further investigation of angustmycin A as a novel anti-melanoma agent. Malignant melanoma is one of the most aggressive types of human cancers. Its ability to metastasize in combination with resistance to conventional anticancer chemotherapy makes melanoma extremely difficult to cure, and the median survival of patients with metastatic melanoma is 8.5 months. [1] [2] [3] A better understanding of the biology behind melanoma aggressiveness is imperative to facilitate the development of novel anti-melanoma strategies.
Melanoma and other cancers cells have been shown to strongly rely on de novo nucleotide biosynthesis 4, 5 and often overexpress several biosynthetic enzymes involved in these pathways. [6] [7] [8] [9] Recently, we have identified a fundamental connection between melanoma invasion and biosynthesis of guanylates, 8 suggesting that distortion of the guanylate metabolism facilitates melanoma progression.
Guanosine monophosphate reductase (GMPR) reduces GMP to one of its precursors, inosine monophosphate (IMP), and depletes intracellular GTP pools (Figure 1a) . We have recently demonstrated that GMPR suppresses melanoma cell invasion and growth of human melanoma cell xenografts. These findings tightly linked guanylate production to the invasive potential of melanoma cells. 8 Of the several enzymes involved in guanylate biosynthesis, inositol monophosphate dehydrogenases 1 and 2 (IMPDH-1, -2), functional antagonists of GMPR (Figure 1a) , have been targeted clinically with several drugs including the most specific one, mycophenolic acid (MPA) and its salt, mycophenolate mofetil (MMF). [10] [11] [12] [13] Nonetheless, prior studies demonstrated that MPA possesses poor anti-tumor activity, 14, 15 and it is primarily used as an immunosuppressing agent in organ transplantation. [10] [11] [12] GMP synthase (GMPS) is the other functional antagonist of GMPR. GMPS catalyzes the amination of xanitol monophosphate (XMP) to GMP to promote GTP synthesis ( Figure 1a) . 16, 17 Most of the studies on GMPS have been performed in bacteria, yeast, and insects, where GMPS has been shown to have a key role in sporulation, pathogenicity, and axon guidance, respectively. [18] [19] [20] Mammalian GMPS has been the subject of several studies addressing its unconventional (GMP-unrelated) roles in the regulation of activity of ubiquitin-specific protease 7 (USP7). [21] [22] [23] [24] However, because of the newly revealed importance of guanylate metabolism in control of melanoma cell invasion and tumorigenicity, 8 GMPS emerges as an attractive target for anti-cancer therapy.
In the late 1950s, a specific inhibitor of bacterial GMPS, angustmycin A (also known as decoyinine), has been isolated from Streptomyces hygroscopius as a potential antibiotic with sporulation-inducing activity in Bacillus subtilis. [25] [26] [27] [28] [29] Its antitumor activity has never been experimentally explored. In the current study, we investigated the role of GMPS in regulation of melanoma invasion and tumorigenicity, and explored the possibility of targeting GMPS by angustmycin A as a novel anti-melanoma strategy.
Results

GMPS controls melanoma cell invasion.
To establish the function of GMPS in melanoma cell invasion, we transduced human metastatic melanoma cells expressing BRAF
V600E
(SK-Mel-28) or NRAS Q61R (SK-Mel-103) with two independent shRNA constructs targeting human GMPS or with a nonsilencing control vector. GMPS depletion was verified by immunoblot ( Figure 1b ) and cells were tested for the ability to invade through Matrigel in a Boyden chamber assay. We found that GMPS depletion reduced the invasive capability of both cell lines to~50% of the vector control (Figure 1b ). Most importantly, in both cell lines, supplementation with 100 μM guanosine abrogated inhibition of invasion caused by GMPS depletion (Figure 1b ). This finding, along with our previous study, 8 demonstrates that changes in the expression levels of guanylate metabolic enzymes critically affects melanoma cell invasion.
To further evaluate the effects of GMPS depletion on invasion, we assessed the ability of cells transduced with control or GMPS shRNAs to degrade extracellular matrix, a pre-requisite for invasion. We found that GMPS-depleted cells demonstrated significantly reduced ability to degrade Figure S1 ). Therefore, GMPS is essential for full-scale invasion of melanoma cells independently of their BRAF/NRAS statuses.
Depletion of GMPS hinders melanoma cells tumorigenicity. We and others demonstrated that invasion accelerates growth of subcutaneous tumor cell xenografts by relieving the physical constraints of the environment. 8, 30 We therefore were interested in whether GMPS controls tumorigenicity of melanoma cells. To this end, SK-Mel-103 and SK-Mel-28 cells transduced with control vector or GMPS shRNAs were inoculated subcutaneously in both flanks of scid/scid (SCID) mice (5 mice per condition). We defined latency as the time from inoculation at which 50% of the injected sites had a palpable tumor (SK-Mel-103) or reached 50 mm 3 (SK-Mel-28). In SK-Mel-103 cells, the latency of GMPS-depleted tumors was 8 days and 15 days (GMPS shRNA-1 and GMPS shRNA-2, respectively) versus 5 days in control cells. SK-Mel-28 cells depleted of GMPS demonstrated tumor latency of 7 days and 10 days (GMPS shRNA-1 and GMPS shRNA-2, respectively) versus 4 days in control cells (Figure 2a) . Additionally, GMPS depletion significantly reduced the growth of tumor xenografts derived from both SK-Mel-103 and SK-Mel-28 cells (Figure 2b ). These data suggest that GMPS has a prominent role in melanoma tumorigenicity.
GMPS expression is increased in human metastatic specimens. To determine whether GMPS expression is associated with melanoma metastases in patients, we assessed its expression levels via immunohistochemistry in 249 human melanoma specimens that we identified previously. 8 All patients were divided into one of three cohorts: primary cutaneous thin melanoma (Breslow thickness ≤ 2 mm); primary cutaneous thick melanoma (Breslow thickness42 mm), and metastatic melanoma, consisting of 36, 46, and 167 patients, respectively. Melanoma specimens were scored for intensity of staining and percentage of stained cells as previously described 8 and the computed IHC index revealed a statistically significant increase in GMPS expression in the metastatic cohort compared with the primary cohorts (Figure 3) . No difference was noted within the primary melanoma cohorts between thin and thick melanomas, suggesting that upregulation of GMPS occurs at metastatic stage of melanoma progression. Furthermore, analysis of publically available microarray data generated by 'The Cancer Genome Atlas' (TCGA) Research Network (http://cancergenome.nih.gov/) revealed that GMPS expression is increased in metastatic melanomas compared with primary lesions (Supplementary Figure S2) , thus validating the expression pattern of GMPS identified by IHC settings.
Taken together, our data are consistent with the hypothesis that GMPS is a driver of invasive metastatic melanoma and thus may represent a novel anti-melanoma target.
Pharmacological targeting of GMPS by angustmycin A decreases invasion. Angustmycin A is a selective GMPS inhibitor that was tested in mice for non-cancer-related properties.
31,32 Thus, we were interested in whether GMPS inhibition via angustmycin A may inhibit melanoma cells invasion. Treatment of SK-Mel-28 and SK-Mel103 cells with 2 mM of Angustmycin A (maximum concentration not affecting proliferation of studied cells) reduced their invasion bỹ 30% compared with vehicle-treated cells (Figure 4a ), mirroring the phenotype caused by GMPS depletion (Figure 1b) . Furthermore, as observed with GMPS depletion, supplementation with 100 μM of guanosine negated the effect of angustmycin A (Figure 4a) . Thus, pharmacological inhibition of GMPS phenocopies the effects of GMPS genetic inhibition on melanoma cells invasive ability and its guanosine dependence.
Angustmycin A suppresses growth of melanoma cell xenografts in SCID mice. Based on the above results, we were interested in the anti-melanoma efficacy of angustmycin A in a preclinical mouse model. Previously, the only in vivo study of angustmycin A was performed in mice to investigate immunological responses to skin allografts. 31 Using data from this paper, we determined the repetitive maximum tolerated dose (rMTD) of angustmycin A in SCID mice as of 120 mg/kg.
IMPDH1 and IMPDH2 are rate-limiting enzymes of de novo guanylate biosynthesis (Figure 1a) and their expression is elevated in tumor cells. 7, 33, 34 A specific inhibitor of IMPDH enzymes, MPA has been used as an immunosuppressant during organ transplant. [35] [36] [37] A better bioavailable form of MPA is its prodrug MMF (over 200% improvement in bioavailability), 38 which has also been proposed as anti-cancer therapy. 39, 40 Therefore, for the purpose of comparison, we evaluated angustmycin A head-to-head with MMF. Since angustmycin A was delivered i.p. we chose the same route of administration for MMF. We selected a therapeutically active dose of MMF (30 mg/kg) based on previous studies and information on bioavailability. 38, 40 SK-Mel-103 and SK-Mel-28 cells were inoculated subcutaneously in both flanks of SCID mice (18 mice/cell line). Once tumors volume reached approximately 100 mm 3 , mice were randomly assigned to one of four groups and treated with daily i.p. injections of angustmycin A (120 mg/kg), MMF (30 mg/kg), or with respective vehicles. Tumor size was measured every other day with a caliper and mice were killed once tumor volume reached 1000 mm 3 or the animals showed signs of morbidity. In SK-Mel-103 cells, angustmycin A treatment resulted in a 36% reduction of xenografts volume while MMF caused only 19% volume reduction compared with respective vehicle controls, (Figure 4b ). In SK-Mel-28 cells, the xenograft volume reduction caused by angustmycin A and MMF were of 62% and 30%, respectively (Figure 4b ). 
Discussion
Melanoma is one of the most aggressive types of human cancers, and its lifetime risk and mortality rates have been steadily increasing for decades. 41, 42 In addition, melanomas are exceptionally resistant to chemotherapy treatment and have a high incidence of relapse. [43] [44] [45] [46] [47] Our previous 8 and current studies have revealed a prominent role of deregulated guanylate pools in melanoma progression. Altered expression of enzymes involved in guanylates biosynthesis priming the cells toward an increase in guanylates production occurs already in primary melanomas (GMPR) and peaks at the metastatic stage (IMPDH2, GMPR, and GMPS) (Wawrzyniak et al 8 and Figure 3 and Supplementary Figure S2) . Manipulation of the expression levels of these enzymes strongly affects the invasive capacity of melanoma cells and ultimately tumor growth.
The formal possibility exists that the effects seen in the current work are due, at least in part, to GMP biosynthesisunrelated functions of GMPS in regulation of the activity of ubiquitin-specific protease 7 (USP7). [21] [22] [23] [24] However, the ability of exogenous guanosine to fully revert all phenotypes caused by GMPS depletion in vitro (Figure 1 ) strongly suggests that guanylate biosynthetic function has the most important role in GMPS-dependent maintenance of invasive and tumorigenic phenotypes of melanoma cells.
As of yet, there is no specific therapy against melanoma with NRAS mutations (~20% of all melanomas), while melanomas with mutant BRAF V600E (~60% of all melanomas) are treated with drugs such as vemurafenib and dabrafenib. However, these agents are not effective in~30% of patients with BRAF V600E melanomas and, of the responders, most relapse within~6 months. 48, 49 Importantly, we identified GMPS as a positive regulator of invasive and tumorigenic potential of melanoma cells irrespective of their BRAF/NRAS mutation status (Figures 1 and 2 ). This evidence combined with the finding that GMPS expression is increased in metastatic melanomas (Figure 3,  Supplementary Figure S2) , makes of GMPS an attractive candidate for therapeutic targeting.
Although the specific GMPS inhibitor, angustmycin A, has been known since the mid-1950s, its antitumor potential has never been thoroughly investigated. Here, we show that angustmycin A treatment affects melanoma invasion in vitro (Figure 4a ) and hinders tumor growth in xenograft mouse model (Figure 4b) . Moreover, like GMPS activity, the effect of angustmycin A does not appear to be subtype specific as it impaired growth of xenografts from cells harboring NRAS Q61R (SK-Mel-103) or BRAF V600E (SK-Mel-28) mutations (Figure 4 ). So far, angustmycin A has been mainly employed as an antibiotic and most of the studies on its activity have been conducted in bacteria or other lower organisms where it was shown that guanylates have a key role in several aspects of their biology including sporulation, pathogenicity, and axon guidance. [18] [19] [20] 28, 29 A single study performed in mice failed to reveal any immune-suppressive efficacy, however, it showed good tolerability. 31 MMF, an inhibitor of IMPDH enzymes, is currently in clinical use as an immunosuppressant although two recent papers suggested that MMF may possess anti-cancer activities in vivo. 39, 40 However, in our head-to-head comparison we demonstrated that the anti-melanoma activity of MMF is significantly lower than that of angustmycin A.
Taken together, our data establish that GMPS levels are increased in human metastatic melanoma specimens and GMPS functions as a driver of both BRAF V600E and NRAS Q61R melanoma cell invasion and tumorigenicity. Furthermore, we for the first time demonstrate that pharmaceutical inhibition of GMPS by angustmycin A has the potential to be effective as an anti-melanoma therapy for tumors carrying BRAF V600E or NRAS Q61R mutations. Therefore, it would be important to evaluate the potential of angustmycin A as an anti-melanoma drug in clinical settings.
Materials and Methods
Cell lines. SK-Mel-28 and SK-Mel-103 human melanoma cell lines were obtained from Memorial Sloan Kettering Cancer Center and cultured in DMEM supplemented with 10% fetal calf serum, 2 mM glutamine and penicillin-streptomycin antibiotics. Cells were kept at 37°C under an atmosphere of 5% carbon dioxide.
Antibodies and other reagents. Mycophenolic acid and guanosine were purchased from Sigma-Aldrich (St. Louis, MO, USA). Angustmycin A was purchased from both Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Enzo Life Sciences (Farmingdale, NY, USA). Mycophenolate Mofetil was purchased from Sigma-Aldrich. The following antibodies were used: mouse monoclonal to GMPS for immunoblotting (Santa Cruz Biotechnology); mouse monoclonal to GAPDH (Ambion, Austin, TX, USA).
Immunoblotting. Whole cell extracts were prepared in NP-40 buffer (20 mM Tris pH7.4, 150 mM NaCl; 1% NP-40, 20 mM NaF) supplemented with 1 mM Naorthovanadate, 1 mM PMSF, and proteases inhibitors (aprotinin 1 μg/ml, pepstatin A 1 μg/ml, and leupeptin 2 μg/ml). Samples (20-80 μg/lane) were resolved on denaturing polyacrylamides gel and transferred onto nitrocellulose membranes. Membranes were incubated o/n at 4°C with primary antibodies, followed by 1 h incubation at RT with the appropriate HRP-conjugated secondary antibody. Signals were visualized using the Pierce ECL western blotting substrate and X-ray films (Thermo Scientific, Rockford, IL, USA).
Immunohistochemistry. Formalin-fixed and paraffin-embedded human melanocytic cells, cutaneous and metastatic melanoma tissues were processed at the Pathology Core Facility (Roswell Park Cancer Institute). Positive and negative control slides were supplied by the Pathology Core Facility and were included with every immunochemistry run. The GMPS antibody (ABCAM, Cambridge, MA, USA, Cat#56530) was visualized with the Novocastra (Newcastle, UK) PowerVision kit, followed by Fast Red (Thermo Scientific). The slides were manually counterstained with hematoxylin. Human tissue specimens were scored for intensity of staining by a board-certified pathologist as described in Wawrzyniak et al. Plasmids and Infection. Lentiviral vectors encoding short-harpins RNA (shRNA) to GMPS along with a non-silencing control vector were purchased from Sigma-Aldrich (shGMPS #1 TRCN0000045942; shGMPS #2 TRCN0000045941). Lentiviral infection protocol was described previously. 50, 51 All infected cells were briefly selected for resistance to puromycin and used in the described assays.
Matrigel-based invasion assay. Invasion assay was performed using the BioCoat Matrigel invasion chambers (BD Bioscience, San Diego, CA, USA) according to the manufacturer's instructions, as described in Wawrzyniak et al. 8 Experiments were performed in duplicates and repeated at least twice.
Combined gelatin degradation assay. Coverslips were coated with warm Oregon Green 488-conjugated gelatin (Invitrogen, Carlsbard, CA, USA) as described in Wawrzyniak et al. 8 Melanoma cells (7.5 × 10 4 ) were seeded on the coverslips and after 16-h incubation at 37°C they were fixed in 4% paraformaldehyde in PBS. After permeabilization in 0.05% Triton X-100 in PBS, cells were stained with rhodamine-conjugated phalloidin (Invitrogen, to visualize actin) and hoechst (Thermo Scientific, to visualize nuclei). Coverslips were mounted Angustmycin A as a novel anti-melanoma agent A Bianchi-Smiraglia et al onto glass slides with aqua-mount media (Polysciences, Warrington, PA, USA). Fluorescent images were captured using a Nikon TE2000-E inverted microscope (Melville, NY, USA) equipped with Roper CoolSnap HQ CCD camera and MetaVue software (Molecular Devices, Sunnyvale, CA, USA).
Animal studies using a subcutaneous xenograft model. SK-Mel-103 or SK-Mel-28 cells expressing control vector or shRNA to GMPS were inoculated subcutaneously in both flanks of 4-to 6-week-old female SCID mice, which are bred and maintained by the in-house transgenic mouse facility at RPCI (1.0x10 6 cells/flank, and 5.0 × 10 6 cells/flank, respectively). For all cohorts, the time of the appearance of tumor ≥ 2 mm in at least one dimension was recorded and tumors were measured thereafter every other day. For drug treatment studies, uninfected SK-Mel-103 or SK-Mel-28 cells were inoculated as described above. When tumors reached 100 mm 3 in size, mice were randomly assigned to different treatment groups and treated with daily i.p. injection of angustmycin A (120 mg/kg in a solution of 10% DMSO in PBS), MMF (30 mg/kg in a suspension of 0.9% benzyl alcohol, 0.9% sodium chloride, 0.5% carboxymethylcellulose, and 0.4% polysorbate 80 in water), or the correspondent vehicle control.
Statistical analysis. Student's t-Test was used to assess the significance of differences in data obtained in cell-based experiments or tumor xenograft growth assay.
